CD274 and cancer: Moreover, cisplatin was also described to induce PD-L1 expression in vitro and in vivo [47,48,49,50,51], a co-inhibitory factor of the immune response which in turn augments the sensitivity of cancer cells to therapies using immune checkpoint inhibitors (ICIs) against PD-L1 [52,53].